IPO Date: Jul 9 to Jul 11 2025
Listing Date: Jul 16 2025
1. Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit;
2. Funding the incremental working capital requirements of our Company;
3. Repayment and/or prepayment, in part or full, of certain of our outstanding borrowings availed by ourCompany; and
4. General Corporate Purposes
-
-
-
-
-
-
-
Maashitla Securities Pvt Ltd.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Asston Pharmaceuticals has informed that the Board of Directors of the Company, on the recommendation of the Audit Committee and in due compliance with the provisions of Section 175 of the Companies Act, 2013 and the rules made thereunder, has accorded its approval by way of a resolution passed by circulation for the appointment of Panchal S K and Associates (Peer Review Certificate No. 018089 and Firm Registration No. 145989W) as the Statutory Auditors of the Company, subject to the approval of the shareholders of the Company at the ensuing General Meeting. The appointment has been made after due consideration of the firm’s professional standing, eligibility, and credentials, in accordance with the applicable provisions of the Companies Act, 2013 and the rules framed thereunder. The disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed as Annexure A and form an integral part of this intimation.’ In compliance with the provisions of Section 175 of the Companies Act, 2013, read with the rules made thereunder and other applicable laws for the time being in force, the delay in submission to the Exchange occurred due to the Company receiving the requisite approval of the majority of Directors on Friday, 27th February, 2026, after business hours. Thereafter, Saturday and Sunday, being non-working days, fell on 28th February, 2026, and 01st March, 2026, respectively. Accordingly, the said approval was intimated to the Exchange on the immediately succeeding working day, Monday, 02nd March, 2026. This disclosure complies with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
In accordance with provisions of Regulation 29(1) (a) SEBI (LODR) Regulation, 2015, Ghushine Fintrrade Ocean has informed that meeting of Board of Directors of company is scheduled to be held on Thursday 14th May, 2026 at registered office of the company at Ground floor -27, Aagam Cross Road, AC Market opposite Star Galaxy near Shrungar Residency, Vesu Abhava road, Surat-395007 to consider and transact the business as stated in the notice of Board Meeting. The important item of agenda to be transacted at the meeting are: a. To consider and approve unaudited Half Yearly Financial Results for the half year ended on 31st march, 2026 with Limited Review Report. b. Any other business with the permission of Chair.
The above information is a part of company’s filings submitted to BSE.
In furtherance to letter dated April 7, 2026, for seeking consent of the Members of the Company by way of remote e‐voting process (‘e-voting’) through postal ballot for increase in Authorized Share Capital and Consequent Amendment to Clause V of the Memorandum of Association of the Company, Camlin Fine Sciences has informed that the above Resolution has been passed by the Members of the Company with requisite majority on May 7, 2026, being the last date of voting. The Voting results of the said Postal Ballot activity through remote e‐Voting, in relation to the aforesaid business, as required under Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 is enclosed. The Scrutinizer's Report dated May 8, 2026, pursuant to Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 is also enclosed. The Voting Results along with the Scrutinizer's Report are also available on the website of the Company: https://www.camlinfs.com/.
No Records Found
The issue size of Asston Pharmaceuticals Ltd. IPO is ₹18.47 - 19.75 crore.
The Asston Pharmaceuticals Ltd. IPO opens for subscription on 2025-07-09 and closes on 2025-07-11.
The price range of Asston Pharmaceuticals Ltd. IPO is ₹115.00 to ₹123.00.
The lot size of Asston Pharmaceuticals Ltd. IPO is 2000 shares.
The registrar of Asston Pharmaceuticals Ltd. IPO is Maashitla Securities Pvt Ltd..
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.